Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Evaluation of effectiveness of orlistat in complexed obesity treatment in teenagers with metabolic syndrome

Cover Page

Abstract


An open, comparative, randomized study of orlistat in the combined treatment of obesity in adolescents with metabolic syndrome
(IIIb phase) was held. Objective: to evaluate the efficacy and safety of the orlistat in adolescents 12-17 years with high risk of cardiovascular
disease and type 2 diabetes. The study included 60 adolescents with obesity and metabolic syndrome. The main group (n=30)
followed a hypocaloric diet and aerobic exercises and took orlistat 120 mg 3 times daily with meals, the control (n=30) group was only
on the non-drug therapy. During the study the anthropometric parameters, lipid, carbohydrate metabolism, blood pressure were evaluated.
All comparisons were performed as two-way, with the critical level of significance ≤ 0,05. Results: After 6 months therapy of orlistat
68% of adolescents achieved clinically meaningful weight loss, that led to the improvement of metabolic parameters. On therapy body
fat decreased by -6600.00 g [-7912.00, -2350.00] in the control group, respectively -2235.50 g [-4700, 00; 667.00] (p=0.011). Orlistat
was well tolerated by patients. Most adverse events (9 of 13 in the intervention group) were mild and can be attributed to the expected
adverse reactions. Conclusion: The study demonstrated clinically significant efficacy (compared with the control group), combined with
good safety records of its use in adolescents 12-17 years old with obesity and metabolic disorders.

  • Дедов И.И., Мельниченко Г.А., Бутрова С.А., Савельева Л.В. и соавт. Ожирение у подростков России // Ожирение и метаболизм. - 2006. - № 4. - С. 30-34.
  • Дедов И. И., Семичева Т.В., Петеркова В.А. Половое развитие детей: норма и патология. - М.: Колор Ит Студио. - 2002.
  • Петеркова В.А., Ремизов О.В. Ожирение в детском возрасте. В кн.: Ожирение: этиология, патогенез, клинические аспекты / Под ред. И.И. Дедова, Г.А. Мельниченко. - М.: Медицинское информационное агентство, 2004. - С. 312-329.
  • Старкова Н.Т., Бирюкова Е.В. Ожирение у подростков. В кн.: Ожирение: этиоло- гия, патогенез, клинические аспекты / Под ред. И.И. Дедова, Г.А. Мельниченко. М.: Медицинское информационное агентство. - 2004. - С. 332-349.
  • Freedman D.S., Dietz W.H., Srinivasan S.R., Berenson G.S. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study // Pediatrics. - 1999. - № 103. - Р. 1175-1182.
  • Daniels S.R., Arnett D.K., Eckel R.H., Gidding S.S., Hayman L.L., Kumanyika S., Robinson T.N., Scott B.J., St. Jeor S., Williams C.L. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment // Circulation. - 2005. - № 111. - Р. 1999-2012.
  • Dietz W.H., Robinson T.N. Overweight children and adolescents // N Engl J Med. - 2005. - № 352. - Р. 2100-2109.
  • Chanoine et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial // JAMA. - 2005. - № 293(23). - Р. 2873-83.
  • Cole T., Bellizzi M.C., Flegal K.M., and Dietz W.H. Establishing a standard definition for child overweight and obesity worldwide: international survey // BMJ. - 2000. - № 320. - Р. 1240-1243.
  • McDuffie J.R. et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African-American and Caucasian adolescents with obesity-related comorbid conditions // J Pediatr Endocrinol Metabol. - 2004. - № 17. - Р. 307-19.
  • Kamath C.C., Vickers K.S., Ehrlich A., McGovern L., Johnson J., Singhal V., Paulo R., Hettinger A., Erwin P.J., Montori V.M. Clinical review: behavioral interventions to prevent childhood obesity: a systematic review and metaanalyses of randomized trials // J Clin Endocrinol Metab. - 2008. - № 93(12). - Р. 4606-15.
  • Kavey R.E., Daniels S.R., Lauer R.M., Atkins D.L., Hayman L.L., Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood // Circulation. - 2003. - № 107. - Р. 1562-1566.
  • Norgren S. et al. Orlistat treatment in obeseprepubertal children: a pilot study // Acta Paediatr. - 2003. - № 92(6). - Р. 666-70.
  • Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion // JCEM. - 2008. -№ 93(12). - Р. 4576-4599.
  • Srinivasan S et al. Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood. The Bogalusa Heart Study // Diabetes. - 2002. - № 51. - Р. 204-9.
  • www.bma.org.uk/ap.nsf/content/childhoodobesity.
  • www.iaso.org.
  • www.who.int.

Views

Abstract - 646

PDF (Russian) - 356


Copyright (c) 2011 Mel'nichenko G.A., Peterkova V.A., Savel'eva L.V., Zubkova N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.